scroll to the top of page

Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.

  Click HERE for a recap of the First Annual Clinical Trials Symposium

Hosted by Thompson Cancer Survival Center on October 29, 2021.  

Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Today, Thompson’s clinical trials department is under the leadership of David Chism, MD and Susan Owenby, RN, CCRP, System Director of Clinical Research. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.

 

Bladder

Protocol Number NCT Number Title Principal Investigator
IMMU 132-13

NCT04527991

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer David Chism, MD

Breast

Protocol Number NCT Number Title Principal Investigator

WO42633  (Astefania)

NCT04873362

A Phase III, Randomized, Double-Blind, Placebo-Controlled clinical trial to evaluate the efficacy and safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at high risk of recurrence following preoperative therapy

David Chism, MD


COVID-19

Protocol Number NCT Number Title Principal Investigator
NCICOVID-19 (N-CCAPS)

NCT04387656

A Longitudinal natural History Study 

David Chism, MD

Gastrointestinal

Protocol Number NCT Number Title Principal Investigator
A021502 NCT02912559 Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as adjuvant therapy for patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair(ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer) David Chism, MD
NRG-GI005 NCT04068103

Phase II/III Study of Circulating tumor DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

 

David Chism, MD

Genitourinary

Protocol Number NCT Number Title Principal Investigator
NRG-GU005 NCT03367702 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for localized intermediate risk prostate cancer Grant Clark, MD
NRG-GU009 NCT04513717 Parallel Phase III Randomized Trials for High Risk Prostate Cancer evaluating De-Intensification for Lower Genomic risk and intensification of concurrent therapy for Higher Genomic risk with radiation (PREDICT-RT*) *Prostate RNA Expression/Decipher to Individualize Concurrent Therapy with Radiation David Chism, MD

Gynecologic 

Protocol Number NCT Number Title Principal Investigator
NRG-GY023  NCT04739800 A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Brook Saunders, MD

 

Leukemia/Lymphoma

Protocol Number NCT Number Title Principal Investigator
AZA-MDS-006 (CONNECT) NCT01688011  The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry David Chism, MD
U2-VEN-207 NCT03801525 ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) David Chism, MD

Liver

Protocol Number NCT Number Title Principal Investigator
D910DC00001 (EMERALD)

NCT03847428

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) David Chism, MD

Lung: Small Cell

Protocol Number NCT Number Title Principal Investigator
NRG-CC003 NCT02635009 A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer Grant Clark, MD
NRG-LU005 NCT03811002 Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab Grant Clark, MD

Lung: Non-Small Cell

Protocol Number NCT Number Title Principal Investigator
D910LC00001 (MeRmaiD1) NCT04385368 A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1) David Chism, MD
D910MC00001 (MeRmaiD2) NCT04642469

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)

David Chism, MD
D4194C00008 (OnTRAX) NCT04381494 Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab David Chism, MD

M14-239

NCT03539536

Phase II, Open-Label Safety and Efficacy Study of Telisotuzuumab Vedotin (ABBV-399) in Subjects with previously Treated c-Met+ NSCLC  Non-Squamous

David Chism, MD

Melanoma

Protocol Number NCT Number Title Principal Investigator
EA6141 NCT02339571 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma David Chism, MD

 

 


Patient Stories

  • First Annual TCSC Clinical Trials Symposium A Success

    “I consider the first annual Clinical Trials Symposium a huge success!” Susie Owenby, System Director of Research for Covenant Health System responded with excitement when asked about the recent event. She went on to explain, “It was well attended by medical providers, ancillary staff, and the community, both in-person and virtually.  Getting the word out […]

  • Understanding the Phases and Types of Clinical Trials

    Content authored by Jessica Severt RN, BSN, Clinical Research Nurse Coordinator at Thompson Cancer Survival Center Clinical Trials: Phases and Types Did you know that most drugs go through at least 3 different levels of clinical trial testing before they are approved?  It may also surprise you to know, that even after a drug is […]

  • Taking the Hospital Home – New Lung Cancer Research

    This content was written by Shelly Abrams, RN, BSN, Clinical Research Coordinator Can Mobile Devices Identify Post-Treatment Problems Early? ON TRAX – Evaluating a mobile technology monitoring device used in patients with inoperable Stage 3 Lung Cancer    Lung cancer is one of the leading causes of cancer deaths in men and women worldwide.  People […]

  • 7 Myths about Clinical Trials Dispelled

    This content was written by Jessica Severt RN, BSN, Clinical Research Nurse Coordinator at Thompson Cancer Survival Center.  Clinical trials are how we discover new and superior treatments, better ways to prevent side effects, and improve survival rates for cancer patients. According to research, only approximately 3-5% of adult cancer patients participate in a clinical […]